NCT07152587View on ClinicalTrials.gov

Randomized Adaptive Platform Trial of Pathogen-Directed Anti-inflammatory Therapy in Severe Community-Acquired Pneumonia(Core Protocal)

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

1,500

Participants

Timeline

Start Date

September 8, 2025

Primary Completion Date

December 31, 2035

Study Completion Date

December 31, 2035

Conditions

Severe Community-acquired Pneumonia (sCAP)

Interventions

DRUG

Low dose steroids

Receive 0.5mg/kg Methylprednisolone

DRUG

Moderate dose steroids

Receive 1.0mg/kg Methylprednisolone

DRUG

Saline (0.9% NaCl)

Saline 100ml

All Listed Sponsors

lead

Qingyuan Zhan

OTHER

NCT07152587 - Randomized Adaptive Platform Trial of Pathogen-Directed Anti-inflammatory Therapy in Severe Community-Acquired Pneumonia(Core Protocal) | Biotech Hunter | Biotech Hunter